CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Total stockholders’ equity attributable to Barinthus Biotherapeutics plc stockholders	Ordinary Shares		Additional Paid-in-Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Noncontrolling Interest	Deferred A Shares Deferred Shares	Deferred B Shares Deferred Shares	Deferred C Shares Deferred Shares
Beginning balance (in shares) at Dec. 31, 2022			37,683,531						63,443	570,987	27,828,231
Beginning balance at Dec. 31, 2022	$ 243,201	$ 242,896	$ 1		$ 379,504	$ (103,243)	$ (33,460)	$ 305	$ 86	$ 8	$ 0	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share based compensation	5,055	5,055			5,055
Issue of ordinary shares, net of issuance costs (in shares)			960,009
Issue of ordinary shares, net of issuance costs	2,035	2,035	$ 0	[1]	2,035
Foreign currency translation adjustments	10,151	10,145					10,145	6
Cancellation of deferred shares (in shares)										(570,987)	(27,828,231)
Cancellation of deferred shares	0				8					$ (8)	$ 0	[1]
Net loss	(73,447)	(73,347)				(73,347)		(100)
Ending balance (in shares) at Dec. 31, 2023			38,643,540						63,443	0	0
Ending balance at Dec. 31, 2023	186,995	186,784	$ 1		386,602	(176,590)	(23,315)	211	$ 86	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share based compensation	4,709	4,709			4,709
Issue of ordinary shares, net of issuance costs (in shares)			1,591,123
Issue of ordinary shares, net of issuance costs	2,163	2,163	$ 0	[1]	2,163
Foreign currency translation adjustments	(2,549)	(2,553)					(2,553)	4
Net loss	(61,183)	(61,074)				(61,074)		(109)
Ending balance (in shares) at Dec. 31, 2024			40,234,663						63,443
Ending balance at Dec. 31, 2024	$ 130,135	$ 130,029	$ 1		$ 393,474	$ (237,664)	$ (25,868)	$ 106	$ 86

[1] Indicates amount less than one thousand